261
Views
18
CrossRef citations to date
0
Altmetric
CASE REPORT

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis

, , , , , & show all
Pages 520-522 | Received 20 Oct 2004, Published online: 08 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Kathleen Ferrer & Natella Rakhmanina. (2013) Neuropsychiatric effects of tenofovir in comparison with other antiretroviral drugs. Neurobehavioral HIV Medicine 5, pages 1-10.
Read now
G. I. T. Cavalcante, V. L. M. Capistrano$suffix/text()$suffix/text(), F. S. D. Cavalcante, S. M. M. Vasconcelos, D. S. Macêdo, F. C. F. Sousa, D. J. Woods & M. M. F. Fonteles. (2010) Implications of Efavirenz for Neuropsychiatry: A Review. International Journal of Neuroscience 120:12, pages 739-745.
Read now
Saskia ME Vrouenraets, Ferdinand WNM Wit, Jacqueline van Tongeren & Joep MA Lange. (2007) Efavirenz: a review. Expert Opinion on Pharmacotherapy 8:6, pages 851-871.
Read now
Gabriele Arendt, Dominique de Nocker, Hans-Juergen von Giesen & Thorsten Nolting. (2007) Neuropsychiatric side effects of efavirenz therapy. Expert Opinion on Drug Safety 6:2, pages 147-154.
Read now
Miguel Goicoechea & Brookie Best. (2007) Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?. Expert Opinion on Pharmacotherapy 8:3, pages 371-382.
Read now

Articles from other publishers (13)

Urs Duthaler, Fabio Bachmann, Claudia Suenderhauf, Tanja Grandinetti, Florian Pfefferkorn, Manuel Haschke, Petr Hruz, Jamal Bouitbir & Stephan Krähenbühl. (2022) Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently. Clinical Pharmacokinetics 61:7, pages 1039-1055.
Crossref
Glenn J. Treisman & Olivia Soudry. (2016) Neuropsychiatric Effects of HIV Antiviral Medications. Drug Safety 39:10, pages 945-957.
Crossref
Michael S. Abers, Wayne X. Shandera & Joseph S. Kass. (2013) Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs. CNS Drugs 28:2, pages 131-145.
Crossref
Hugo Martins de Oliveira, Adriani Paganini Damiani, Renata de Oliveira Dias, Pedro R.T. Romão & Vanessa M. Andrade. (2014) Effect of antiretroviral drugs on the DNA damage in mice. Environmental Toxicology and Pharmacology 37:1, pages 390-395.
Crossref
F Kaestner, K Anneken, C Mostert, D Reichelt, M Rothermundt, S Evers & I W Husstedt. (2012) Depression associated with antiretroviral drug therapy in HIV: case report and overview. International Journal of STD & AIDS 23:6, pages e14-e19.
Crossref
Christopher A. Kenedi & Harold W. Goforth. (2011) A Systematic Review of the Psychiatric Side-Effects of Efavirenz. AIDS and Behavior 15:8, pages 1803-1818.
Crossref
Pedro R. T. Romão, Joelson C. Lemos, Jeverson Moreira, Gisele de Chaves, Morgana Moretti, Adalberto A. Castro, Vanessa M. Andrade, Carina R. Boeck, João Quevedo & Elaine C. Gavioli. (2009) Anti-HIV Drugs Nevirapine and Efavirenz Affect Anxiety-Related Behavior and Cognitive Performance in Mice. Neurotoxicity Research 19:1, pages 73-80.
Crossref
Michael PfallerAlan Street. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition 2675 2701 .
Martin Vogel & Mark Nelson. (2009) HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?. European Journal of Medical Research 14:Suppl 3, pages 36.
Crossref
Emilio L. Streck, Giselli Scaini, Gislaine T. Rezin, Jeverson Moreira, Celine M. Fochesato & Pedro R. T. Romão. (2008) Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Metabolic Brain Disease 23:4, pages 485-492.
Crossref
Sofia A. Pereira, Umbelina Caixas, Teresa Branco, Isabel Germano, Fátima Lampreia, Ana L. Papoila & Emília C. Monteiro. (2008) Efavirenz concentrations in HIV‐infected patients with and without viral hepatitis. British Journal of Clinical Pharmacology 66:4, pages 551-555.
Crossref
Karen Dahri & Mary H H Ensom. (2007) Efavirenz and Nevirapine in HIV-1 Infection. Clinical Pharmacokinetics 46:2, pages 109-132.
Crossref
. (2005) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 15:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.